Spirometry as an objective tool for nasal patency

Spirometry can be used as an objective tool for measuring nasal patency. it is sensitive, easy to perform, comfortable to patient The only limitation being that it only can be done in institution.     

Clinical History, Skin Prick Test and RAST in the Diagnosis of Birch and Timothy Pollinosis

The diagnostic efficacy of clinical history (CH), skin prick test (SPT) and RAST was estimated in relation to nasal and conjunctival provocation tests (NPT, CPT) in 69 patients with seasonal rhinoconjunctivitis. The extracts used were freeze-dried, and biologically standardized birch and timothy allergen preparations matched to the extracts on Phadebas RAST discs. Based on single determinations the sensitivity, specificity and predictive values were calculated. There were highly significant (P less than 0.001) correlations between all parameters: NPT, CPT, CH, SPT and RAST. For birch the combination of SPT and RAST made the PTs superfluous as both sensitivity and specificity then reached 100%. With timothy the sensitivity was 97% and with the addition of CH 100%. However, the specificity was only 79% through combining CH, SPT and RAST. The present study using the same standardized allergen preparation in all tests showed a good correlation between indirect test results and provocation tests.     

鼻内镜下等离子低温射频治疗常年性变应性鼻炎的临床观察

目的探讨鼻内镜下等离子低温射频治疗常年性变应性鼻炎(PAR)的疗效及其优越性。方法在鼻内镜下用等离子低温射频治疗PAR48例,按照海口会议修订的“过敏性鼻炎诊断和疗效评定标准”,用计分法分别评定其疗效。结果该组48例术后随访半年进行评价,其中显效27.1%(13/48),有效58.3%(28/48),无效14.6%(7/48),总有效率为85.4%。疗效评分显示治疗前平均总分为(9.58±1.69)分,治疗后为(5.63±1.15)分(P<0.05)。结论鼻内镜下等离子低温射频烧灼筛前神经终末区域治疗PAR,具有简便、安全等优点,短期效果显著,特别适用于临床上应用抗组胺类药物及鼻内应用糖皮质激素治疗效果不甚理想及由于各种原因不能长期接受抗组胺类药物及鼻内应用糖皮质激素治疗的患者;但长期疗效有待进一步研究。     

组织工程化口腔粘膜的构建技术初步研究

目的　探索组织工程化口腔粘膜的构建方法。方法　用 Dispase中性蛋白酶分离提取未长毛的 SD乳鼠硬腭口腔粘膜细胞 ,用角化细胞培养液对口腔粘膜细胞进行培养 ,以自制藻酸钠薄膜作为支架材料构建组织工程化的口腔粘膜。结果　 Dispase中性蛋白酶可较好地分离提纯口腔粘膜细胞 ,用 Dispase消化酶分离获取上皮后 ,再用胰蛋白酶消化上皮为单细胞的最佳时间为 10 m in,过低的细胞密度不易形成克隆 ,鼠口腔粘膜细胞培养的最适密度为 1.5× 10 5/ cm2 。角化细胞培养液能对鼠口腔粘膜细胞进行培养 ,且没有成纤维细胞污染 ;口腔粘膜细胞在藻酸钠薄膜上生长良好。结论　利用角化细胞培养液作为培养基 ,藻酸钠薄膜作为支架材料可成功构建组织工程化口腔粘膜     

胃肠粘膜外翻缝合加浆肌层缝合的研究

胃肠、胆肠及肠肠吻合,采用粘膜外翻缝合外加浆肌层缝合256例,与同期采用Albert-Lambert缝合318例对比。结果:外翻缝合育操作简单、顺手、省时、线头残留少等优点。     

Gln与rhGh对肝硬化病人肠黏膜屏障的影响

目的观察Gln与rhGh各单独应用及联合应用对肝硬化病人小肠黏膜屏障形态学和功能学的影响。方法20个肝硬化病人随机分成四组,给予等氮等热量营养支持7d,Gln+rhGh组口服Gln[0.3g/(Kg·d)]和皮下注射rhGh(10U/d);Gln组口服Gln;rhGh组应用皮下注射rhGh;CONT对照组应用相应安慰剂。观察治疗前后患者小肠黏膜通透性和十二指肠黏膜绒毛高度和隐窝深度的变化,分别比较。结果Gln+rhGh组治疗后小肠黏膜通透性有显著性的降低(P<0.05),且显著低于其他三组(P<0.05);十二指肠黏膜绒毛高度和隐窝深度有显著性的增高(P<0.05),且显著高于其他三组(P<0.05)。结论Gln与rhGh联合应用能减低肠道黏膜的通透性和维持其形态学的完整。     

Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis

BACKGROUND: Rofleponide palmitate is an esterified glucocorticosteroid pro-drug with a promising pre-clinical profile designed to deliver topical airway treatment for allergic rhinitis and asthma in a novel manner. Thus, the rofleponide palmitate pro-drug is designed to provide topical exposure of the mucosa to the inactive lipophilic drug, which would be locally metabolized to the more hydrophilic and readily cleared drug rofleponide. OBJECTIVE: To examine whether rofleponide palmitate affects nasal symptoms and peak inspiratory flow (PIF) in a pollen-season model of allergic rhinitis and to compare any such effects with those of another glucocorticosteroid (i.e., budesonide). METHODS: During the pollen-free season, 40 patients with strictly seasonal allergic rhinitis received topical nasal spray treatment with an aqueous solution of rofleponide palmitate 400 microg and an aqueous solution of budesonide 128 microg once daily for 10 days in a double-blind, placebo-controlled, and crossover study. After 3 days of drug treatment, individualized allergen challenges were given once daily for 7 days while the treatment continued. The washout periods between each of the challenge series were 2 weeks. Nasal symptoms and PIF were recorded in the morning and evening, as well as 10 and 20 min after each allergen challenge. The mean recordings obtained during the last 3 days of the allergen-challenge series, when symptoms were established and when the treatment had lasted for 8-10 days, were used in the analysis. RESULTS: Both active treatments reduced nasal symptoms and improved nasal PIF compared with placebo (P<0.01-0.001). There was no overall difference in efficacy between rofleponide palmitate 400 microg and budesonide 128 microg. CONCLUSIONS: Topical treatment with aqueous solutions of rofleponide palmitate attenuates nasal symptoms and improves nasal PIF in allergic rhinitis. The overall efficacy of 400 microg of rofleponide palmitate is similar to that of 128 microg of budesonide in the pollen-season model used in this study.     

直肠癌癌旁移行粘膜细胞动力学变化

应用氚－胸腺嘧啶核苷体外双标记放射自显影法，对１５例直肠癌旁移行粘膜与非移行粘膜作细胞动力学的比较观察。结果表明，移行粘膜的标记指数与非移行粘膜比差异非常显著（Ｐ＜０．０１），在细胞增殖周期和ＤＮＡ合成期时间亦有差别。提示移行粘膜细胞增殖异常，可视为潜在癌前期粘膜。